Who are the key gene therapy investors?

This blog post has been written by the person who has mapped the gene therapy investment market in a clean and beautiful presentation

Gene therapy investors are reshaping biotech with selective, high-value bets despite market volatility.

The investment landscape in gene therapy has undergone dramatic shifts in 2024-2025, with venture funding dropping 45% to $773 million while major pharmaceutical companies continue aggressive M&A activity exceeding $3 billion. Understanding who controls capital allocation in this space reveals critical insights for entrepreneurs seeking funding and investors evaluating opportunities.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Who are the top gene therapy investors globally right now?

The gene therapy investment hierarchy is dominated by a select group of institutional investors who consistently write the largest checks and shape market direction.

EQT Life Sciences and Forbion lead the venture capital tier, with EQT co-leading SpliceBio's $135 million Series B and Forbion spearheading Beacon Therapeutics' $170 million round. Arch Venture Partners maintains its position through strategic investments like Arbor Biotechnologies' $73.9 million Series C, while specialized funds including Syncona and Bain Capital Life Sciences focus on platform technologies with proven clinical potential.

Corporate venture arms have become increasingly aggressive, with Sanofi Ventures, Novartis Venture Fund, and Roche Venture Fund co-investing in major rounds to secure future partnerships. These pharmaceutical giants recognize that early investment provides preferred access to breakthrough technologies before competitive bidding drives acquisition prices higher.

Geographic leaders include Sofinnova Partners dominating European investments through deals like Purespring Therapeutics' $105 million Series B, while emerging players like Double Point Ventures target earlier-stage opportunities with investments such as GEMMA Biotherapeutics' $34 million seed round.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

Which companies have these investors backed and what do they actually do?

Top-tier investors concentrate on companies developing transformative delivery platforms rather than single-asset biotechs, recognizing that platform technologies offer multiple shots on goal and higher return potential.

SpliceBio represents the archetype of investor-preferred companies, having raised $135 million for its ALIGATER™ protein splicing platform that enables large gene delivery through dual AAV vectors. Their lead program SB-007 targets Stargardt disease, but the platform's ability to address delivery limitations across multiple indications attracted co-investment from EQT Life Sciences, Sanofi Ventures, Roche Venture Fund, and Novartis Venture Fund.

Beacon Therapeutics secured $170 million from Forbion for X-linked Retinitis Pigmentosa therapies using advanced AAV vectors, while Tune Therapeutics raised $175 million for epigenome editing that modifies gene expression without DNA sequence changes. Purespring Therapeutics attracted $105 million from Sofinnova Partners for AAV-based kidney disease treatments, with lead program PS-002 targeting IgA Nephropathy.

Platform diversity reflects investor risk management, with Atsena Therapeutics raising $150 million for broad gene therapy development, GEMMA Biotherapeutics securing $34 million for novel approaches, and AavantiBio obtaining $107 million from Bain Capital Life Sciences for specialized applications targeting underserved patient populations.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

How much funding did each investor provide to their portfolio companies?

Investment amounts reveal strategic priorities, with lead investors typically contributing 20-40% of round totals while co-investors provide 5-15% stakes to maintain portfolio diversification.

In SpliceBio's $135 million Series B, EQT Life Sciences likely contributed $40-50 million as co-lead, with Sanofi Ventures providing $20-30 million and Roche Venture Fund adding $15-25 million based on typical syndicate structures. Forbion's leadership of Beacon Therapeutics' $170 million round suggests a $50-70 million investment, representing their largest gene therapy bet to date.

Bain Capital Life Sciences' $107 million Series A in AavantiBio represents a substantial solo lead investment, while Arch Venture Partners' participation in Arbor Biotechnologies' $73.9 million Series C likely involved a $15-25 million contribution alongside other syndicate members. Sofinnova Partners' lead in Purespring's $105 million Series B probably required a $30-45 million commitment.

Corporate venture funds typically invest smaller amounts for strategic access, with Novartis Venture Fund, Sanofi Ventures, and Roche Venture Fund each contributing $10-20 million per round to maintain meaningful positions without overwhelming their portfolios with single-asset concentration risk.

What terms and conditions do these investors demand?

Gene therapy investment terms have shifted toward investor-friendly structures reflecting market uncertainty, with liquidation preferences, board control, and milestone-based tranching becoming standard practice.

Most Series B and C rounds include 1x non-participating liquidation preferences with weighted average broad-based anti-dilution protection, giving investors downside protection while preserving upside participation. Lead investors typically secure two board seats in larger rounds, with additional observer rights for major co-investors to monitor clinical and regulatory progress.

Corporate investors often negotiate strategic terms beyond equity stakes, including co-development rights, exclusive licensing options for specific territories or indications, and first refusal on follow-on therapeutics developed using the same platform. These provisions can significantly impact future financing options and exit strategies for entrepreneurs.

Milestone-based funding has become increasingly common, with 30-50% of committed capital released upon clinical trial initiation, regulatory approval achievements, or partnership execution. This structure protects investors from development failures while ensuring companies have sufficient runway to reach value-inflection points that support higher valuations in subsequent rounds.

Which regions see the most gene therapy investment activity?

North America dominates gene therapy investment with 41.78% of global revenue and $15.7 billion in recent investment activity, driven by favorable regulatory frameworks and deep venture capital markets.

The United States maintains overwhelming leadership through established biotech hubs in Boston, San Francisco, and San Diego, where proximity to world-class research institutions, experienced management teams, and specialized service providers creates ecosystem advantages. Major investors like Arch Venture Partners, Bain Capital Life Sciences, and RA Capital Management concentrate their activities in these regions, facilitating knowledge transfer and syndicated investment opportunities.

Europe lags significantly with $2.9 billion in investment compared to US levels, though specific markets show promise. Spain's SpliceBio represents European success, while Switzerland and the Netherlands attract investment through companies like those in Forbion's portfolio. The European Investment Bank and national innovation funds provide additional capital, but venture ecosystems remain fragmented across national boundaries.

Asia-Pacific emerges as the fastest-growing region with 16.37% CAGR, led by China's aggressive government funding, Japan's pharmaceutical industry partnerships, and South Korea's advanced manufacturing capabilities. However, regulatory complexity and intellectual property concerns limit Western investor participation, creating opportunities for region-specific funds and corporate ventures.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

Are pharmaceutical giants investing in gene therapy, and how much?

Thirteen of the fifteen largest pharmaceutical companies by market capitalization actively invest in gene therapy through acquisitions exceeding $3 billion in 2024 and substantial venture partnerships.

Novartis leads pharmaceutical investment with the $1.1 billion acquisition of Kate Therapeutics for muscular dystrophy and cardiomyopathy treatments, plus active venture participation through Novartis Venture Fund in companies like SpliceBio. Roche's $1.5 billion acquisition of Poseida Therapeutics demonstrates commitment to allogeneic CAR-T development, while their venture arm co-invests in promising platforms.

Astellas structured a sophisticated $2.2 billion milestone deal with AviadoBio, providing $30 million upfront for option rights to AVB-101 frontotemporal dementia therapy. This approach allows pharmaceutical companies to secure future access while minimizing immediate capital requirements and development risk.

Bristol Myers Squibb, AbbVie, Vertex Pharmaceuticals, and other major players maintain dedicated gene therapy investment teams, typically allocating $200-500 million annually across venture investments, partnerships, and acquisitions. Corporate venture funds provide strategic access to emerging technologies while internal R&D teams focus on later-stage development and commercialization capabilities.

If you want to build or invest on this market, you can download our latest market pitch deck here

Which gene therapy technologies attract the most investor funding?

Protein splicing platforms, epigenome editing, and in vivo CAR-T technologies dominate investor interest due to their potential to address fundamental delivery and manufacturing limitations plaguing the industry.

SpliceBio's ALIGATER™ platform attracted $135 million because protein splicing enables delivery of large genes that exceed traditional AAV packaging limits, potentially unlocking treatments for previously undruggable conditions. Tune Therapeutics' $175 million raise reflects investor enthusiasm for epigenome editing that modifies gene expression without permanent DNA changes, reducing safety concerns while maintaining therapeutic efficacy.

Advanced AAV vector engineering continues attracting substantial investment, with companies developing tissue-specific targeting, reduced immunogenicity, and improved manufacturing processes. Tessera Therapeutics has raised approximately $600 million for gene writing technology using mobile genetic elements, while Mammoth Biosciences secured $465 million for ultracompact CRISPR platforms.

In vivo CAR-T development represents an emerging hotspot, with multiple companies developing approaches to generate CAR-T cells directly in patients rather than through complex ex vivo manufacturing. This technology could dramatically reduce costs and expand patient access, making it particularly attractive to both venture investors and pharmaceutical partners seeking competitive advantages.

How much total capital was invested in gene therapy during 2024?

Gene therapy venture funding totaled $773 million across 20 rounds in 2024, representing a 45% decline from 2023's $1.4 billion but reflecting industry consolidation toward higher-quality opportunities.

The $773 million figure excludes pharmaceutical acquisitions and corporate partnerships, which added approximately $3 billion in additional capital through deals like Novartis-Kate Therapeutics ($1.1 billion), Roche-Poseida ($1.5 billion), and Astellas-AviadoBio (up to $2.2 billion in milestones). Including all investment types, total gene therapy capital exceeded $4 billion in 2024.

Average round sizes increased to $38.7 million, indicating investor preference for later-stage companies with clinical proof-of-concept rather than early-stage platform development. Mega-rounds exceeding $100 million represented 40% of total funding, with deals like Beacon Therapeutics ($170 million), Tune Therapeutics ($175 million), and Atsena Therapeutics ($150 million) dominating capital allocation.

Cell and gene therapy combined attracted $15.2 billion in 2024, marking a 30% increase from 2023 when including manufacturing, platform, and enabling technology investments alongside therapeutic development companies.

What is the 2025 investment trajectory compared to 2024?

Early 2025 indicators suggest continued selective investment patterns, with major rounds like SpliceBio's $135 million Series B demonstrating sustained appetite for proven platforms while overall deal volume remains constrained.

Q1 2025 data shows mega-rounds ($100+ million) continue dominating, representing approximately 50% of venture funding despite fewer total transactions. This concentration reflects investor risk aversion, with capital flowing primarily to companies demonstrating clinical efficacy, established partnerships, or breakthrough platform technologies that address fundamental industry challenges.

Corporate venture activity appears stable, with pharmaceutical companies maintaining strategic investment programs while increasing acquisition selectivity. The SpliceBio round's syndicate including Sanofi Ventures, Novartis Venture Fund, and Roche Venture Fund demonstrates continued corporate interest in platform technologies offering multiple development pathways.

Geographic diversification shows promise, with European companies like SpliceBio attracting substantial international investment and Asia-Pacific companies beginning to access Western capital markets. However, total 2025 funding likely will not exceed 2024 levels without significant improvement in public market conditions and commercial therapy adoption rates.

If you need to-the-point data on this market, you can download our latest market pitch deck here

What recent exits and returns have gene therapy investors achieved?

Gene therapy exits have delivered mixed results, with high-profile failures like Bluebird Bio's $30 million sale contrasting against selected pharmaceutical acquisitions providing substantial returns to early investors.

Bluebird Bio's acquisition by private equity for $30 million represents a catastrophic loss from its previous $10 billion peak valuation, highlighting the risks investors face when commercial adoption fails to meet expectations. Pfizer's discontinuation of Beqvez hemophilia therapy and termination of its Sangamo partnership further illustrate commercial challenges affecting investor returns.

Successful exits remain limited to strategic acquisitions, with Novartis' $1.1 billion Kate Therapeutics purchase and Roche's $1.5 billion Poseida acquisition providing meaningful returns to venture investors. However, specific return multiples remain confidential, and many successful companies represent later-stage investments with more modest appreciation potential.

IPO activity remains virtually nonexistent due to public market skepticism about gene therapy commercialization timelines and profitability. Companies requiring additional capital increasingly rely on private funding rounds or strategic partnerships rather than public offerings, limiting exit opportunities for venture investors seeking liquidity.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

Are new investors entering the gene therapy space in 2025?

New investor entry remains limited, with most fresh capital coming from existing players expanding their gene therapy allocations rather than new funds entering the space.

Family offices and growth equity firms represent the primary source of new investment capital, attracted by later-stage opportunities with reduced technical risk. These investors typically co-invest alongside established venture funds rather than leading rounds, providing additional capital for scale-up activities while relying on specialized partners for technical due diligence.

Corporate venture arms continue expanding, with additional pharmaceutical companies establishing dedicated gene therapy investment teams to secure access to emerging technologies. However, these represent extensions of existing corporate strategies rather than fundamentally new investor categories entering the market.

Government and sovereign wealth funds show increasing interest in gene therapy infrastructure and manufacturing capabilities, particularly in regions seeking to build domestic biotechnology capabilities. These investments typically focus on platform development and manufacturing capacity rather than individual therapeutic programs, creating opportunities for companies with scalable technologies.

What are the investment forecasts for gene therapy in 2026?

Industry experts predict potential recovery in gene therapy investment as manufacturing costs decrease, more therapies demonstrate commercial success, and new delivery technologies address fundamental industry limitations.

Investment volume could return to $2-3 billion annually if market conditions improve, driven by technological breakthroughs in in vivo delivery systems, manufacturing automation, and platform technologies enabling multiple therapeutic programs. Geographic expansion, particularly in Asia-Pacific markets, may provide additional growth as regulatory frameworks mature and local investor sophistication increases.

Technology focus will likely concentrate on CNS and neurological disorders, ophthalmology applications, rare genetic diseases, and cancer immunotherapy combinations. These areas offer clearer regulatory pathways, defined patient populations, and potential for premium pricing that justifies development costs and investment requirements.

The gene therapy market is projected to reach $12.8 billion by 2026, creating substantial opportunities for investors who can identify and support companies developing the platforms and technologies that will capture this growth. Success will depend on selecting companies with proven technologies, experienced management teams, and clear paths to commercialization rather than betting on unproven concepts or early-stage development programs.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Conclusion

Sources

1. GEN - Top Five Gene Editing Companies
2. SpliceBio - $135M Series B Announcement
3. DealForma - Gene Therapy R&D Partnerships 2024
4. C&EN - Jim Wilson's Gene Therapy Company
5. Bain Capital - AavantiBio $107M Series A
6. Mordor Intelligence - Gene Therapy Market Report
7. Labiotech - Gene Therapy Investment Trends
8. SNS Insider - Gene Therapy Platform Market
9. GEN - Top 10 Best-Selling Gene Therapies
10. ASGCT - Q4 2024 Industry Report
11. BioSpace - Cell and Gene Therapy Investment Surge
12. DDW - Cell and Gene Therapy 2025 Predictions
13. JPMorgan - Biopharma Outlook Q4 2024
14. Alliance RM - Q1 2025 Sector Snapshot
15. BioPharma Dive - SpliceBio Series B Analysis
16. Reuters - Gene Therapy Investment Challenges
17. BioPharma Dive - Pfizer Beqvez Discontinuation
18. Fierce Biotech - Pfizer Sangamo Partnership End
19. PackGene - Gene Therapy Investment Decline Analysis
20. Cell & Gene - Market Evolution Analysis
21. Labiotech - Gene Therapy Investment Slowdown
22. Pharma's Almanac - Gene Therapy Industry Reset
23. BioSpace - Investment Recovery Trends